Core Viewpoint - The company's Q3 2025 performance met market expectations, with a revenue of 21.79 billion yuan and a Non-GAAP net loss of 2.7 billion yuan, indicating ongoing reform effectiveness and operational improvements [1]. Financial Performance - Q3 2025 revenue reached 21.79 billion yuan, with a Non-GAAP net loss of 2.7 billion yuan, aligning with market expectations [1]. - The company delivered 87,071 vehicles in Q3 2025, achieving a comprehensive gross margin of 13.9%, up 3.9 percentage points quarter-on-quarter, and an automotive gross margin of 14.7%, up 4.4 percentage points, marking the best quarterly performance since Q1 2023 [1]. - R&D and selling, general, and administrative (SG&A) expenses were 2.39 billion yuan and 4.19 billion yuan, respectively, with R&D expenses decreasing by approximately 600 million yuan quarter-on-quarter, while SG&A expenses increased due to new model cycles [1]. Development Trends - The company expects Q4 deliveries to reach 120,000 to 125,000 vehicles, maintaining a high level of sales [1]. - By 2026, the company anticipates a strong product cycle and internal operational improvements, with existing models expected to support sales recovery [1]. - The company plans to launch three SUV models (ES9, ES7, L80) in Q2-Q3 2026, aiming to strengthen its position in the pure electric vehicle market [1]. Cash Flow and Financing - The company reported positive operating cash flow and free cash flow in Q3, supported by a strong product cycle [2]. - On September 17, the company completed a public offering of new shares, raising $1.16 billion to fund core technology development, new platform and model development, and infrastructure expansion, enhancing its financial stability [2]. Profit Forecast and Valuation - Current valuations for U.S. and Hong Kong stocks are projected at 0.7x and 0.8x P/S for 2026, respectively [2]. - The company adjusted its non-GAAP profit forecasts for 2025/26 from -10.27 billion yuan and 5.43 billion yuan to -13.17 billion yuan and 3.67 billion yuan, maintaining an outperform rating [2]. - Target prices for Hong Kong and U.S. stocks were reduced by 9% to 62 HKD and 8 USD, respectively, indicating potential upside of 32% and 46% from current prices [2].

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $37.3 million, an increase of 101% compared to $18.5 million in Q3 2024, primarily driven by the inclusion of Greenbrook operations following the acquisition [16][19] - On an adjusted pro forma basis, revenue increased by 11% year-over-year [16] - Gross margin decreased to 45.9% from 75.6% in the prior year quarter, mainly due to the lower margin of Greenbrook's clinic business [18][19] - Net loss for Q3 2025 was $9.4 million or $0.13 per share, compared to a net loss of $13.3 million or $0.44 per share in the prior year [19] Business Line Data and Key Metrics Changes - Revenue from Greenbrook clinics was $21.8 million, up 25% on an adjusted pro forma basis compared to the prior year [6][18] - NeuroStar business revenue was $15.5 million, with system revenue at $3.5 million and treatment session revenue at $10.5 million [16][19] - NeuroStar treatment session utilization grew 11% year-over-year, indicating strong demand despite a decrease in treatment session revenue due to customer inventory adjustments [17][18] Market Data and Key Metrics Changes - SPRAVATO volumes increased sequentially in Q3 compared to Q2, with 84 of 89 eligible clinics now offering the therapy [8][18] - The company is optimizing its SPRAVATO offering by adjusting billing methods based on state and payer reimbursement dynamics [8][22] Company Strategy and Development Direction - The company is focused on integrating and optimizing operations post-Greenbrook acquisition, aiming to improve efficiencies and capture full value from combined businesses [5][15] - Strategic partnerships, such as with Elite DNA and Transformations Care Network, are expected to expand NeuroStar's footprint and enhance treatment access [23][24] - The company is committed to operational excellence and cash optimization, with initiatives like self-check-in kiosks and AI integration to improve patient experience and reduce costs [12][13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute on priorities and create value for patients and shareholders, highlighting strong momentum in the Greenbrook integration and operational improvements [15][25] - The company anticipates achieving positive cash flow from operations in Q4 2025, with projected revenue guidance of $40 million to $43 million [20][22] Other Important Information - The company has received additional funding under its existing debt agreement, strengthening its cash position [20] - New York State Medicaid began covering NeuroStar TMS therapy for adults with major depressive disorder, expanding access to over 5 million members [15] Q&A Session Summary Question: What is driving the growth dynamics between Greenbrook and NeuroStar sites? - Management noted that Greenbrook clinics saw nearly 28% growth year-over-year, driven by SPRAVATO and TMS segments, while NeuroStar's treatment utilization increased but did not translate to revenue growth due to inventory adjustments [28][29] Question: What changed regarding gross margin expectations post-Greenbrook merger? - Management explained that the lower gross margin is due to the inclusion of Greenbrook's lower-margin clinic business, while NeuroStar's cost structure remains stable [30][31] Question: Can operational efficiencies be quantified in terms of cost savings? - Management indicated that while specific savings have not been quantified, investments in automation and technology are expected to drive long-term efficiencies [35][38] Question: How is the adolescent indication performing and what role does the provider connection program play? - Management reported an uptick in adolescent patient starts, largely driven by the provider connection network, which has increased awareness among primary care physicians [56][57]